Dejen Nureye1, Eyob Tekalign2, Nebeyi Fisseha1, Tarekegn Tesfaye1, Workineh Woldeselassie Hammeso1. 1. Department of Pharmacology and Toxicology, School of Pharmacy, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Aman, Southwest Ethiopia. 2. Department of Medical Laboratory sciences, College of Medicine and Health Sciences, Mizan-Tepi University, Mizan-Aman, Southwest Ethiopia.
Abstract
BACKGROUND: Since drug resistance makes controlling malaria parasites a major challenge, these pioneering researchers explore and discover new novel drugs from a variety of sources. As a result, this study aimed to assess the anti-plasmodial activity of hydroalcoholic crude extract and solvent fractions of Zehneria scabra roots in mice infected with Plasmodium berghei. METHODS: The antimalarial activity and safety profile of Zehneria scabra extracts were tested in a mouse model using four-day suppressive, prophylactic, and rane's tests against chloroquine-sensitive Plasmodium berghei. Mice were divided into five groups at random: group I received distilled water (10 mL/kg), group II, III, and IV received 200, 400, and 600 mg/kg of the extract, respectively, and group V received chloroquine (25 mg/kg). The antimalarial activity of the extract was determined using parasitemia levels, survival time, rectal temperature, and weight variation. RESULTS: At all dose levels, the crude extract and solvent fractions of Zehneria scabra showed significant (p<0.05 to p<0.001) chemosuppression, with the crude extract and butanol fraction showing the highest chemosuppression (73.09% and 74.09%, respectively). Apart from suppressing parasitemia, the extract also increased survival time and secured packed cell volume reduction substantially (p<0.05 to p<0.001), while the crude extract had no significant impact on body weight or rectal temperature reduction in four-day suppressive and prophylactic models. CONCLUSION: The result designated that Zehneria scabra is endowed with significant antimalarial activity. These results thus support the traditional use of Zehneria scabra, for the treatment of malaria.
BACKGROUND: Since drug resistance makes controlling malaria parasites a major challenge, these pioneering researchers explore and discover new novel drugs from a variety of sources. As a result, this study aimed to assess the anti-plasmodial activity of hydroalcoholic crude extract and solvent fractions of Zehneria scabra roots in mice infected with Plasmodium berghei. METHODS: The antimalarial activity and safety profile of Zehneria scabra extracts were tested in a mouse model using four-day suppressive, prophylactic, and rane's tests against chloroquine-sensitive Plasmodium berghei. Mice were divided into five groups at random: group I received distilled water (10 mL/kg), group II, III, and IV received 200, 400, and 600 mg/kg of the extract, respectively, and group V received chloroquine (25 mg/kg). The antimalarial activity of the extract was determined using parasitemia levels, survival time, rectal temperature, and weight variation. RESULTS: At all dose levels, the crude extract and solvent fractions of Zehneria scabra showed significant (p<0.05 to p<0.001) chemosuppression, with the crude extract and butanol fraction showing the highest chemosuppression (73.09% and 74.09%, respectively). Apart from suppressing parasitemia, the extract also increased survival time and secured packed cell volume reduction substantially (p<0.05 to p<0.001), while the crude extract had no significant impact on body weight or rectal temperature reduction in four-day suppressive and prophylactic models. CONCLUSION: The result designated that Zehneria scabra is endowed with significant antimalarial activity. These results thus support the traditional use of Zehneria scabra, for the treatment of malaria.
Authors: Guiomar Pérez-Moreno; Juan Cantizani; Paula Sánchez-Carrasco; Luis Miguel Ruiz-Pérez; Jesús Martín; Noureddine El Aouad; Ignacio Pérez-Victoria; José Rubén Tormo; Víctor González-Menendez; Ignacio González; Nuria de Pedro; Fernando Reyes; Olga Genilloud; Francisca Vicente; Dolores González-Pacanowska Journal: PLoS One Date: 2016-01-06 Impact factor: 3.240